

2nd Australian site for Nanomab-PDL-1 Phase 1 therapeutic trial in lung cancer

- ***Ethics Committee approval received from Hollywood Private Hospital in Perth, WA***
- ***Patient recruitment to commence shortly***
- ***Phase 1 study in 21 patients designed to evaluate the safety and efficacy of ¹⁷⁷Lu-RAD 204 in PD-L1 positive non-small cell lung cancer (NSCLC)***
- ***Follows recent announcement that recruitment for the trial will also commence shortly at Princess Alexandra Hospital in Brisbane***
- ***The 2nd Australian site increases geographic availability of the trial and therefore is expected to accelerate its recruitment***

Sydney, Australia – 27 December 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has received Human Research Ethics Committee (HREC) approval from the Hollywood Private Hospital in Perth, WA that will see it become the 2nd Australian site for its RAD 204 Phase 1 therapeutic study targeting PD-L1-positive non-small cell lung cancer (NSCLC).

The study, entitled “Study of the Safety and Tolerability of ¹⁷⁷Lu-RAD 204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer”, is a first-In-human dose escalation trial of ¹⁷⁷Lu-RAD 204 designed to evaluate the safety and efficacy of this novel radiotherapeutic in eligible individuals with advanced NSCLC, the most common type of lung cancer.

As announced to the ASX on 22 December 2023, the trial will open at the Princess Alexandra Hospital in Brisbane on 4 January 2024.

With the addition of the Perth site, the geographic availability of the trial widens and therefore recruitment is expected to accelerate accordingly. The trial is being supported by leading oncology care provider GenesisCare.

“It’s an excellent piece of validation for the interest in and potential of this trial to have another site already committed to participating,” said Radiopharm’s Chief Executive Officer & Managing Director, Riccardo Canevari. “It gives us added confidence in the speed at which we’ll be able to recruit as we aim to deliver a new and improved solution for one of the most common cancer diagnoses in Australia as well as worldwide.”

Approximately 300,000 new lung cancer cases are expected to be diagnosed in the US by the end of 2023, 81% of which are estimated to be NSCLC patients¹, while it is estimated that there were more than 2.2 million cases of lung cancer in 2020².

About Radiopharm Theranostics

¹ American Cancer Society. *Cancer Facts and Figures 2023*. Atlanta; American Cancer Society: 2023.

² <https://www.wcrf.org/cancer-trends/lung-cancer-statistics/>

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm has been listed on ASX (RAD) since November 2021. The company has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world's leading universities and institutes. The pipeline has been built based on the potential to be first-to-market or best-in-class. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumour cancers including breast, kidney and brain. Learn more at [Radiopharmtheranostics.com](https://radiopharmtheranostics.com).

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>
Twitter – <https://twitter.com/TeamRadiopharm>
Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>
InvestorHub – <https://investorhub.radiopharmtheranostics.com/>

